Systematic Review of the Side Effects Associated With Anti-HER2-Targeted Therapies Used in the Treatment of Breast Cancer, on Behalf of the EORTC Quality of Life Group-Reference-Cited by-同舟云学术

Systematic Review of the Side Effects Associated With Anti-HER2-Targeted Therapies Used in the Treatment of Breast Cancer, on Behalf of the EORTC Quality of Life Group

Published:2015-12-18 Issue:3 Volume:11 Page:277-292
ISSN:1776-2596
Container-title:Targeted Oncology
language:en
Short-container-title:Targ Oncol

Author:

Sodergren Samantha C.,Copson Ellen,White Alice,Efficace Fabio,Sprangers Mirjam,Fitzsimmons Deborah,Bottomley Andrew,Johnson Colin D.

Funder

EORTC Quality of Life Group

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s11523-015-0409-2.pdf

Reference48 articles.

1. Widakowich CCGJ, de Azambuja E, Dinh P, Awada A (2007) Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist 12(12):1443–1455

2. Slamon D, Godolphin W, Jones LA, Holt JA et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244(4905):707–712

3. Cobleigh M, Vogel C, Tripathy D, Robert N, Scholl S, Fehrenbacher L, Wolter J, Paton V, Shak S, Lieberman G, Slamon D (1999) Multinational study of the efficacy and safety of humanized anti-HERs monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17(9):2639–2648

4. Goldhirsch A, Coates AS, Gelber RD et al (2006) First—select the target: Better choice of adjuvant treatments for breast cancer patients. Ann Oncol 17:1772–1776

5. Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gómez H, Dinh P, Fauria K, Van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horváth Z, Coccia-Portugal M, Domont J, Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber RD, Piccart-Gebhart M, Neo AST (2012) Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 9816:633–640

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A randomized controlled trial of shared decision-making treatment planning process to enhance shared decision-making in patients with MBC;Breast Cancer Research and Treatment;2024-06-10

2. IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy;Clinical Cancer Research;2024-04-05

3. A Systematic Review of Health-Related Quality of Life in Women with HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab;PharmacoEconomics - Open;2024-03-15

4. Does the Argentine Tango Sustainably Improve Cancer-Associated Fatigue and Quality of Life in Breast Cancer Survivors?;Cancers;2023-11-30

5. Enhancing Oncology Side Effect Management Using a Remote Monitoring System;Clinical Journal of Oncology Nursing;2023-09-25